Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 9/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GCGR | P47871 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18022488 | 0.94 | MAPT (0.44) | MAPTKMT2AMEN1CASP3TRPV1 | |
| SCHEMBL16056424 | 0.93 | CA12 (0.49) | MAPTKMT2AMEN1CASP3TRPV1 | |
| SCHEMBL18022487 | 0.91 | MAPT (0.45) | MAPTKMT2AMEN1CASP3TRPV1 | |
| SCHEMBL16056200 | 0.91 | MAPT (0.44) | MAPTKMT2AMEN1CASP3TRPV1 | |
| SCHEMBL16056330 | 0.89 | MRGPRX4 (0.50) | KDM4ESMN1; SMN2SSTR5KCNH2LMNA | |
| SCHEMBL17535658 | 0.88 | MAPT (0.41) | MAPTKMT2AMEN1CASP3TRPV1 | |
| SCHEMBL16056031 | 0.88 | MAPT (0.41) | MAPTKMT2AMEN1CASP3TRPV1 | |
| SCHEMBL17535594 | 0.87 | SSTR5 (0.41) | MAPTKMT2AMEN1CASP3TRPV1 | |
| SCHEMBL16616462 | 0.87 | CHRNA7 (0.41) | MAPTKMT2AMEN1CASP3TRPV1 | |
| SCHEMBL16056320 | 0.87 | SSTR5 (0.46) | MAPTKDM4ESSTR5KCNH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113609-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. | 2023-04-13 | — | — | US | disclosed |
| EP-4069702-A1 | SSTR5 ANTAGONISTS | Kallyope, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2021113368-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113368-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| EP-3055309-B1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-13 | — | — | EP | disclosed |
| US-9751878-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-9751878-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-9751878-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| US-8759539-B2 | Substituted bicyclic amines for the treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2427465-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120041012-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120041012-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20110207737-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP | 2011-08-25 | — | — | US | disclosed |
| EP-2358200-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010129729-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129729-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010056717-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056717-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207737-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | SSTR5, TAAR5, MC5R | MAPT 3990/4885KMT2A 1742/4885MEN1 1153/4885 |
| US-20230113609-A1 | SSTR5 ANTAGONISTS | SSTR5, GLP1R, GPR119 | MAPT 1483/4885KMT2A 2300/4885MEN1 2406/4885 |
| US-20120041012-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | SSTR5, SSTR2, GPR119 | MAPT 4006/4885KMT2A 2457/4885MEN1 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.